Published in final edited form as:

Calcif Tissue Int. 2013 October ; 93(4): 338–347. doi:10.1007/s00223-013-9723-9.

Bone Collagen: New Clues to its Mineralization Mechanism From Recessive Osteogenesis Imperfecta

David R. Eyre and Mary Ann Weis

University of Washington, Dept. of Orthopaedics & Sports Medicine, 1959 NE Pacific St., PO Box 356500, Seattle, WA 98195

Abstract

Until 2006 the only mutations known to cause osteogenesis imperfecta (OI) were in the two genes coding for type I collagen chains. These dominant mutations affecting the expression or primary sequence of collagen 1(I) and 2(I) chains account for over 90% of OI cases. Since then a growing list of mutant genes causing the 5–10% of recessive cases has rapidly emerged. They include *CRTAP*, *LEPRE1* and *PPIB*, which encode three proteins forming the prolyl 3-hydroxylase complex; *PLOD2* and *FKBP10*, which encode respectively lysyl hydroxylase 2 and a foldase required for its activity in forming mature cross-links in bone collagen; *SERPIN H1*, which encodes the collagen chaperone HSP47; *SERPIN F1*, which encodes pigment epithelium-derived factor required for osteoid mineralization; and *BMPI*, which encodes the type I procollagen C-propeptidase. All cause fragile bone in infancy, which can include over-mineralization or under-mineralization defects as well as abnormal collagen post-translational modifications. Consistently both dominant and recessive variants lead to abnormal cross-linking chemistry in bone collagen.

These recent discoveries strengthen the potential for a common pathogenic mechanism of misassembled collagen fibrils. Of the new genes identified, eight encode proteins required for collagen post-translational modification, chaperoning of newly synthesized collagen chains into native molecules or transport through the endoplasmic reticulum and Golgi for polymerization, cross-linking and mineralization. In reviewing these findings, we conclude that a common theme is emerging in the pathogenesis of brittle bone disease of mishandled collagen assembly with important insights on post-translational features of bone collagen that have evolved to optimize it as a biomineral template.

Keywords

Collagen; Bone; Cross-Linking; Osteogenesis Imperfecta; Post-Translational modifications

Introduction

Despite intensive study over 50 years the exact molecular mechanism of mineralization of bone collagen to form an intimate ordered biocomposite remains elusive. In particular, the question is still contested whether the bone collagen itself has evolved special features or is essentially generic and passive in a process largely driven by extrafibrillar inhibitors of

Corresponding Author: deyre@uw.edu, Tel. 206.543.4700, Fax 206.685.4700.

Disclosure of Financial Conflicts of Interest:

Neither of the authors has any financial relationship with the organization that sponsored the research or with any other organizations whose area of activity may be affected or perceived to be influenced by the results of this review.

The authors have stated that they have no conflict of interest.

solid-phase calcium phosphate nucleation, and so acts primarily as a structural constraint on nanocrystal growth not a nucleator (Fig. 1). Here we summarize recent genetic discoveries on osteogenesis imperfecta (OI) that we believe reinforces a long-held view that highly evolved post-translational features of bone collagen itself are intimately involved in regulating the structure of the eventual composite of polymeric collagen embedded with oriented nanocrystal plates of hydroxyapatite [1,2]. When steps in any of the complex pathways modulating the unique post-translational chemistry and assembly of collagen in bone go wrong, severe OI can result [3–16].

Osteogenesis Imperfecta (OI) and Bruck Syndrome

Recent advances in OI research are reviewed in [17]. Most OI cases are caused by dominant mutations in one of the two genes encoding type I collagen that affect both amount and structure of the assembled matrix collagen. Though a systemic defect, fragile bone is the most pronounced tissue consequence. For many years no causative genes were known for the ~10% of recessive cases, beyond a few cases of parental mosaicism for type I collagen mutations. This changed with the discovery that mutations in *CRTAP* (encodes cartilage-associated protein) caused recessive OI [3]. This protein forms a complex with prolyl 3-hydroxylase 1 (P3H1) and peptidyl prolyl isomerase B (PPIB or cyclophilin B) in the endoplasmic reticulum (ER) [18], which is responsible for 3-hydroxylating single prolines in the collagen 1(I) and 2(I) chains at 1(I) Pro986 and 2(I) Pro707 [19]. In rapid succession, further mutations in *CRTAP* and mutations in *LEPRE1* (which encodes P3H1) and *PPIB* (encodes cyclophilin B) were found to cause recessive OI [4–8]. Mutations in the other genes listed in Table 1 soon followed [9–16, 20–23]. Bruck syndrome, which exhibits the bone fragility of OI and joint contractures, results from defective lysyl hydroxylase 2 activity caused by mutations in either *PLOD2*, which encodes the enzyme [24], or *FKBP10*, which encodes a member of another class of ER resident peptidyl prolyl isomerases [11,12]. Null mutations in both genes produce close phenocopies of Bruck syndrome both clinically and in terms of an abnormal collagen cross-linking. Only the cross-linking products of telopeptide lysine aldehydes are present in the structural bone collagen of affected patients [14,25]. The cross-linking of cartilage type II collagen, however, appears not to be affected, whereas ligament type I collagen is.

Mutations in the gene *SERPINH1* encoding the well-known ER collagen chaperone HSP47 (heat-shock protein 47) and in *SERPINF1*, which encodes pigment epithelium-derived factor (PEDF), were also found to cause recessive OI [10,20,21]. The latter protein, PEDF, is produced and secreted by osteoblasts, can bind to collagen, is anti-angiogenic, circulates in the serum and, when missing, osteoid seams fail to mineralize.

More recently mutations in *BMPI*, which encodes the protease responsible for cleaving the C-propeptides from type I collagen, were found to cause recessive OI cases [15,16]. In addition to these seven genes, all of which are involved in collagen type I processing or its mineralization, a homozygous mutation in the gene encoding SP7/Osterix (a transcription factor required for osteoblast differentiation) also causes recessive OI [26]. Mutations in LRP5 (low density lipoprotein receptor-related protein [5]) can cause low bone mass without OI features [27] or osteosclerosis [28], depending on the mutation, through effects on WNT signaling specific to bone. Most recently the radiographically distinguished dominant variant OI type V was shown to be caused by a heterozygous mutation in a gene for osteoblast-specific transmembrane protein, IFITM5 [22,23] (Table 1). The function of this protein in osteoblasts is still unclear.

In summary, most OI cases whether recessive or dominant are associated with a defective molecular assembly of bone collagen. The new findings reveal and highlight the importance

of understanding the mechanistic intricacies controlling the post-translational quality of collagen assembly in bone. Can these new genetic insights also aid in understanding whether certain post-translational properties unique to bone collagen are essential for its characteristic pattern of nanocrystal mineralization?

Fibrillar architecture and cross-linking of bone collagen

Collagen type I of bone has the same translated primary sequence as that in skin, tendon, and other tissues. The template for the type I collagen polymeric fibril is collagen type V of composition $[(1(V))_2, 2(V)]$ in developing bone with increasing amounts of $1(XI)$ substituting for $1(V)$ in mature bone [29]. The functional significance of this isomorphic developmental change in chain usage structurally and biologically, is unknown. In mature bone as in other tissues, the molar ratio of type I/type V/XI collagens is about 30/1 [30].

Intermolecular covalent cross-links between collagen telopeptide and helical domains are essential for fibril strength. Bone collagen presents a unique chemical profile of cross-linking since the telopeptide lysines, which lysyl oxidase converts to reactive aldehydes, are only 50% hydroxylated compared with 0% in skin type I collagen and 100% in type I and II collagens of cartilages [31]. The mechanism regulating this is unclear. Consequently the initial divalent and mature trivalent cross-links of bone collagen give a distinctive pattern on peptide analysis with about equal amounts of mature pyrroles and pyridinolines in human bone collagen [32]. Fig. 2A summarizes the pathway initiated by reactive aldehydes generated in telopeptides by lysyl oxidase. Both lysine and hydroxylysine aldehydes react with helical cross-linking site lysine/hydroxylysine residues. Pyridoline cross-links are found in the collagen of many tissues including bone but are absent from normal skin and cornea. Pyrrole cross-links appear to be restricted to bone and high-load tendons among major connective tissue [32,33]. The ratio of pyrroles to pyridinolines has been shown to vary between bone types, for example between osteoporotic and control human bone, with a high pyrrole content associated with a finely meshed trabecular architecture [34]. In Bruck syndrome, the lack of telopeptide hydroxylysines prevents pyridoline and pyrrole formation and results in a cross-linking profile that resembles that of type I skin collagen [14,25]. Bruck syndrome is also distinguished clinically by neonatal joint contractures, which it is reasonable to suspect may be a consequence of an altered cross-linking chemistry in tendons and related supporting tissues.

We conclude that pyrrole cross-links contribute unique properties to bone collagen for its role in producing an intimate mineral microcrystal/protein composite. The pyrrole structure predicted from the molecular mass and other properties of isolated cross-linked pyrrole peptides [31], including its likely mechanism of formation by interaction of two divalent cross-links is a 3-hydroxypyrrole (Fig. 2A). Model N-alkylated 3-hydroxypyrroles are highly reactive, for example they can spontaneously form a dimer or add another aldehyde moiety through their C2 carbon [35]. (Aldehyde addition is the basis of the p-DIMAB colorimetric reaction product used to assay these cross-links in collagen [36]). Pyrroles have the potential therefore to progress to more complex multivalent cross-links as collagen fibrils mature. If telopeptide lysines become more hydroxylated than normal as part of the general over-modification seen in many OI variants as a consequence of delayed triple-helix folding [14], then the pyridoline to pyrrole ratio will increase in bone in concert with the reported increase in HP/LP ratio [37]. Conceivably this could produce a more brittle mineralized composite with lower threshold for micro-damage and crack propagation and hence increase bone fragility. Post-translational over-modification of lysine residues in collagen is well recognized in OI cases caused by mutations in *COL1* genes, *CRTAP*, *LEPRE1* and *PPIB* [3–7]. It should be noted, however, that such collagen over-modifications in OI studies are usually based on the properties of collagens synthesized by

skin fibroblasts in culture. When compared with collagen from bone tissue of such patients the results can be misleading, particularly when 3Hyp levels are being reported (Eyre & Weis, unpublished).

Lysyl hydroxylase 2, FKBP65 and Bruck Syndrome

Figure 2B shows the four cross-linking sites in the type I collagen molecule, two telopeptide and two triple-helical, through which intermolecular bonds can form when polymerized in fibrils. Lysyl hydroxylase 2 (LH2) is solely responsible in osteoblasts for telopeptide lysine hydroxylation. When effectively null due to mutations in *PLOD2* no hydroxylysine aldehyde cross-links can form and the result is Bruck Syndrome 2 [24]. It turns out that mutations in FKBP10 can produce a very similar pathology (Bruck Syndrome 1) through a lack of telopeptide hydroxylase activity [13,14,25]. The most likely mechanism is that the protein it encodes, FKBP65, a peptidyl prolyl isomerase, is required to fold lysyl hydroxylase 2 correctly for it to be active in the ER. Note that lysyl hydroxylase 1 is primarily responsible for hydroxylating the helical cross-linking site lysines [38] so a delayed collagen triple-helix folding can also result in the increased HP/LP pyridinoline ratio seen in other forms of OI. Conversely, null mutations in *PLOD1* (encodes LH1), which cause Ehlers-Danlos Syndrome VIA, result in a very low HP/LP ratio in bone [38]. The bone collagen defects in Ehlers-Danlos Syndrome type VIA, both Bruck Syndrome variants and other forms of OI can be detected as abnormal ratios of HP/LP in patients' urine [14,24,39].

Collagen Prolyl 3-hydroxylation

Early in evolution, prolyl hydroxylase activity added functionality to ancestral collagens. Thermal stability of the triple helix was increased by hydrogen bonding through 4-hydroxyproline (4Hyp) residues [40]. Though 3-hydroxyproline (3Hyp) was also present (at about one residue per type I collagen chain and 10 per type IV collagen chain) its function is still essentially unknown. Not until a lack of 3Hyp in type I collagen of *CRTAP* null mice had led to *CRTAP* mutations as a cause of recessive human OI did interest focus on possible functions for 3Hyp.

The finding of several sites of partial 3Hyp occupancy in types I and II collagen molecules spaced D-periodically (234 ± 3 residues) implied a possible role in fibril assembly [19]. Peptide-binding experiments indicated selective affinity between like-regions containing a 3Hyp residue [41]. From such evidence and other considerations, including the outward pointing direction from the triple-helix of the 3Hyp 3-hydroxyl in a-Gly3Hyp4Hyp- triplet [42], short-range hydrogen bonding between collagen triple-helices was considered a possibility [19]. This implied a role in supramolecular assembly.

Fig. 3 shows identified sites of 3Hyp in type I collagen molecules (clade A gene products). Only one (A1, Pro986) is fully hydroxylated. Partially occupied A2, A3 and A4 are spaced D-periodically apart. More, unrelated 3Hyp sites are present in the type V/XI collagen

1(V) and 1(XI) chains, which are clade B gene products. Three that are heavily occupied are shown (B1 – B3). Multiple other GPP sequences in 1(V) have also revealed low levels of 3Hyp occupancy that vary in occupancy with cellular origin [43]. When packed in fibrils the A2, A3, A4 D-periodic sites align in the molecular overlap region, which also contains the A1 site (Fig. 3). The 3Hyp locations are shown placed to scale relative to the uranyl acetate-stained banding pattern of a collagen fibril and to sites where certain SLRPs (small leucine-rich proteoglycans) bind to collagen fibrils. Fibromodulin and lumican bind close to the a and c bands where telopeptide to helix cross-links also occur [44,45].

Although 3Hyp is found throughout animal phyla from the most primitive sea sponges [46], the Pro986 substrate did not appear until early chordates (Eyre and Weis, unpublished findings). This coincides with the appearance of the *CRTAP* gene and just before vertebrates and bone emerged [47]. The Pro986 3Hyp site therefore appears to be a newly recognized substrate when CRTAP and the P3H1/CRTAP/PPIB complex emerged [19]. To speculate, this acquired Pro986 modification may have helped equip collagen molecules for a polymeric architecture that was better organized to enable ordered hydroxyapatite nanocrystal growth within fibrils. An effect on cross-linking and molecular packing is one possibility we are exploring.

Alternatively the P3H1/CRTAP/PPIB complex may function primarily as a chaperone that aids in native collagen molecule assembly [17]. The consequences of the defective complex include ER distress, the unfolded protein response (UPR) and disrupted cell level regulation of bone formation and turnover. This could be the primary cause or at least a significant contributor to OI pathobiology. The two concepts are not mutually exclusive and lack of Pro986 3Hyp and ER distress probably both contribute.

The collagen-specific chaperone HSP47 and *SERPINH1* mutations

The exact mechanism by which *SERPINH1* mutations result in brittle bones is unclear, but clearly it involves collagen misassembly. The mutations reported in human OI, L78P, and in dog OI, L326P, both result in sequence changes at the active site through which HSP47 binds to the collagen triple-helix as shown from the crystal structure of the complex [48].

Since HSP47 binds strongly only to a native triple-helix at specific sites containing arginine it acts as a quality control for folding and prevents premature aggregation of native procollagen molecules until after they are transported from ER to Golgi and released at low pH [48].

The cross-linking of bone collagen from the OI Dachshund [9] shows abnormalities consistent with a defective molecular assembly and post-translational chemistry (Eyre & Weis, unpublished). The mechanism and significance of this continue to be explored.

SERPINF1/PEDF, OI type VI and osteoid mineralization

OI type VI is characterized by a unique bone histomorphometry, with large seams of unmineralized osteoid and an abnormal lamellar pattern [49]. Collagen biochemistry seems normal as far as it has been investigated. The causative defect (mutations in *SERPINF1*) disrupts PEDF, a secreted protein apparently required for mineralization of osteoid [20,21]. A mechanistic role for PEDF as a chaperone in the osteoblast ER also remains a possibility, so post-translational effects on collagen in bone cannot yet be ruled out.

However, it seems more likely that the defect is downstream from matrix collagen assembly and involves a regulatory step of mineral deposition extracellularly. Understanding the mechanism may reveal another pathway and signaling defects through which mutations can cause OI.

BMP1 and collagen C-propeptide processing defects

Autosomal dominant collagen type I mutations (COLA1 and COLA2) that alter the C-propeptide cleavage site sequence result in relatively mild OI with an abnormally high mineral density in patients on DXA scans [50]. Retention of propeptide sequences conceivably could result in more space for mineral within and between fibrils, which may explain the high bone density. Altered collagen cross-linking remains a possibility.

Recessive mutations in *BMP1*, which encodes the collagen type I C-propeptidase, also cause OI with high bone density presumably through a similar mechanism of delayed propeptide removal and disrupted fibril assembly and mineralization [13,14]. Note that BMP1 processes other matrix molecules including lysyl oxidase (*LOX*) activation by removal of its N-terminal propeptide domain [51]. So more than one mechanism may be operating.

IFITM5 / Bril and OI type V

A single autosomal dominant new mutation in another gene *IFITM5* (interferon-induced transmembrane protein 5) was most recently shown to cause OI type V in multiple individuals and families [22,23,57]. This heterozygous mutation in the 5'-UTR adds 5 amino acids to the N-terminus of the signal peptide, which is predicted to have gain of function effects. The gene encodes a small transmembrane protein highly restricted to mineralized tissue and known to be expressed in osteoblasts at the point in bone formation when mineral is deposited [52,53]. The findings strongly suggest a specific role in the control of osteoblast expression and the mineralization pathway of bone and cartilage. Curiously, the protein product of *IFITM5* (Bril – bone restricted ifitm-like protein) is associated with yet another peptidyl prolyl isomerase in the 15-member human FKBP gene family, FKBP19 (encoded by *FKBP11*) [53].

Fibril-associated small leucine-rich proteoglycans (*SLRP*) in bone

Small leucine-rich proteoglycans (SLRPs) are a widely distributed and diverse group of 18 matrix proteins evolved from a common ancestor that share collagen-binding domains [53]. Decorin, biglycan, lumican, fibromodulin, keratan and osteoadherin are among the SLRPs widely distributed and found in bone matrix where they are bound to collagen fibril surfaces. From studies on mice null for either or both decorin and biglycan, these molecules are important regulators of fibril growth and size limits in many tissues [54]. Osteoadherin is limited to bone and dentin and is deposited just before mineralization occurs [55]. Osteoadherin-null mice have not been described so the significance of this molecule in mineralization and bone function is unclear. Work on fibromodulin, a related class II *SLRP*, indicates a role in tendon in regulating fibril size and lysyl oxidase-mediated cross-linking chemistry [45]. Though mutations in SLRPs have not been found in OI, their role in shaping the fibrillar collagen architecture and material properties of extracellular matrices is clear.

Implications for bone fragility

In this review we summarize the defective steps in collagen assembly that can result in a childhood brittle bone phenotype. With the growing knowledge a repeated theme is emerging of abnormal cross-linking when bone collagen is examined. We end with a hypothesis that disturbed cross-linking from the normal equal mix of lysine aldehyde and hydroxylysine aldehyde structures is a fundamental feature of the bone pathology in OI. Clearly collagen strength rests heavily on its cross-linking but other properties of bone including ductility and resistance to micro-damage and crack propagation may depend on the unique pattern of lysyl oxidase mediated cross-links that characterize normal bone collagen of higher vertebrates. The placement of cross-links and chemical lability of a significant fraction of them (those formed from lysine aldehydes) may be required to produce a malleable framework in which mineral nanocrystals can grow optimally within the fibrils. This concept is in accord with conclusions drawn from ultrastructural and material property observations on fragile bone from the oim mouse which lacks an $\alpha 2(I)$ chain and deposits $\alpha 1(I)$ trimeric type I collagen [56].

Clearly, too, other mechanisms produce low bone mass and risk of fragility fractures through signaling pathway defects as evidenced by the SP7/osterix [26] and WNT pathway

[27,28] mutations. So it is also possible that defects in collagen assembly have downstream effects on cell matrix interactive signaling as well as inherent structural defects in the collagen matrix itself.

Implications for Mineral Deposition

An association between the presence of 3-hydroxyproline residues in collagen with mineralization can be traced back to silica deposition by Porifera, the most primitive class of multicellular animals [46]. Indeed, it has been proposed that hydrogen bonding between orthosilicic acid and the vicinal two hydroxyls in –Gly-3Hyp-4Hyp– sequences in the meters long silica spicules of cloud sponges can act as a collagen-based nucleation template for silica crystal growth [46].

It is possible that this same unique peptide sequence has continued to act as a surface template for orienting mineral nanocrystal deposition throughout collagen evolution. It seems more likely, however, that 3Hyp evolved to add structural stability and/or order to collagen assembly, which in turn influenced the packing arrangement and cross-linking of molecules in fibrils to provide an orderly and malleable microenvironment for accommodating mineral crystallite growth. A potential role in orienting solid phase mineral growth nevertheless deserves some attention.

Future Challenges

- Defining how tissue-specificity in the chemistry and placement of cross-linking bonds is regulated in bone collagen and whether cross-link irregularities are a common mechanism underlying bone fragility in OI. Are pyrrole cross-links important for the unique material properties of bone and is their loss a determining factor in the bone fragility of OI?
- Establishing the physicochemical and biological advantages that 3Hyp residues added to the collagen triple helix both ancestrally and through evolution.
- Defining the mechanisms by which fibril-associated SLRPs (small leucine-rich proteoglycans) regulate the lateral and longitudinal growth of collagen fibrils in general and in bone specifically. Do such proteins influence collagen cross-linking and fibril mineralization?
- The biggest challenge will be proving cause and effect relationships between the altered post-translational features of collagen in OI, and material properties as a basis for predicting increased bone fragility. The clues we have suggest that abnormal cross-linking may be a common consequence but is this a critical change affecting material strength, a marker of altered molecular packing which in turn affects mineral organization, or a side show? Multidisciplinary collaborations and genetic approaches will continue to be vital for progress in this rapidly advancing field.

Acknowledgments

Research reported in this publication from the authors' laboratory was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Awards AR36794 and AR37318. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

1. Glimcher, MJ. Specificity of the molecular structure of organic matrices in mineralization. In: Sogannes, RF., editor. *Calcification in Biological Systems*. Washington, DC: American Association for the Advancement of Science; 1960.
2. Glimcher MJ. Bone: Nature of the calcium phosphate crystals and cellular, structural, and physical chemical mechanisms in their formation. *Rev Mineral Geochem*. 2006; 64:223–282.
3. Morello R, Bertin TK, Chen Y, Hicks J, Tonachini L, Monticone M, Castagnola P, Rauch F, Glorieux FH, Vranka J, Bächinger HP, Pace JM, Schwarze U, Byers PH, Weis MA, Fernandes RJ, Eyre DR, Yao Z, Boyce BF, Lee B. CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta. *Cell*. 2006; 127(2):291–304. [PubMed: 17055431]
4. Barnes AM, Chang W, Morello R, Cabral WA, Weis MA, Eyre DR, Leikin S, Makareeva E, Kuznetsova N, Uveges TE, Ashok A, Flor AW, Mulvihill JJ, Wilson PL, Sundaram UT, Lee B, Marini JC. Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. *N Engl J Med*. 2006; 355:2757–2764. [PubMed: 17192541]
5. Cabral WA, Chang W, Barnes AM, Weis MA, Scott MA, Leikin S, Makareeva E, Kuznetsova NV, Rosenbaum KN, Tift CJ, Bulas DI, Kozma C, Smith PA, Eyre DR, Marini JC. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. *Nature Genet*. 2007; 39(3):359–365. [PubMed: 17277775]
6. Baldridge D, Schwarze U, Morello R, Lenington J, Bertin TK, Pace JM, Pepin MG, Weis M, Eyre DR, Walsh J, Lambert D, Green A, Robinson H, Michelson M, Houge G, Lindman C, Martin J, Ward J, Lemyre E, Mitchell JJ, Krakow D, Rimo DL, Cohn DH, Byers PH, Lee B. *CRTAP* and *LEPRE1* mutations in recessive osteogenesis imperfecta. *Hum Mutat*. 2008; 29(12):1435–1442. PMC2671575. [PubMed: 18566967]
7. vanDijk FS, Nesbitt IM, Zwikstra EH, Nikkels PGJ, Piersma SR, Fratantoni SA, Jimenez CR, Huizer M, Morsman AC, Cobben JM, van Roij MHH, Elting MW, Verbeke MIJL, Wijnaendts LCD, Shaw NJ, Högl W, McKeown C, Sistermans EA, Dalton A, Meijers-Heijboer H, Pals G. PPIB mutations cause severe osteogenesis imperfecta. *Am J Hum Genet*. 2009; 85:521–527. [PubMed: 19781681]
8. Barnes AM, Carter EM, Cabral WA, Weis MA, Chang W, Makareeva E, Leikin S, Rotimi CN, Eyre DR, Raggio CL, Marini JC. Lack of cyclophilin B in osteogenesis imperfecta with normal collagen folding. *N Engl J Med*. 2010; 362:521–528. [PubMed: 20089953]
9. Drögemüller C, Becker D, Brunner A, Haase B, Kircher P, Seeliger F, Fehr M, Baumann U, Lindblad-Toh K, Leeb T. A missense mutation in the *SERPINH1* gene in Dachshunds with osteogenesis imperfecta. *PLoS Genet*. 2009; 5(7):e1000579. [PubMed: 19629171]
10. Christiansen HE, Schwarze U, Pyott SM, AISwaid A, Al Balwi M, Alrasheed S, Pepin MG, Weis MA, Eyre DR, Byers PH. Homozygosity for a missense mutation in *SERPINH1*, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta. *Am J Hum Genet*. 2010; 86:389–398. [PubMed: 20188343]
11. Alanay Y, Avaygan H, Camacho N, Utine GE, Boduroglu K, Aktas D, Alikasifoglu M, Tuncbilek E, Orhan D, Bakar FT, Zabel B, Superti-Furga A, Bruckner-Tuderman L, Curry CJ, Pyott S, Byers PH, Eyre DR, Baldridge D, Lee B, Merrill AE, Davis EC, Cohn DH, Akarsu N, Krakow D. Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta. *Am J Hum Genet*. 2010; 86:551–559. [PubMed: 20362275]
12. Kelley BP, Malfait F, Bonafe L, Baldridge D, Homan E, Symoens S, Willaert A, Elcioglu N, Van Maldergem L, Verellen-Dumoulin C, Gillerot Y, Napierala D, Krakow D, Beighton P, Superti-Furga A, De Paepe A, Lee B. Mutations in FKBP10 cause recessive osteogenesis imperfecta and Bruck syndrome. *J Bone Miner Res*. 2011; 26(3):666–672. [PubMed: 20839288]
13. Barnes AM, Cabral WA, Weis M, Makareeva E, Merta EL, Leikin S, Eyre D, Trujillo C, Marini JC. Absence of FKBP10 in recessive type XI OI leads to diminished collagen cross-linking and reduced collagen deposition in extracellular matrix. *Hum Mutat*. 2012; 33:1589–1598. [PubMed: 22718341]
14. Schwarze U, Cundy T, Pyott SM, Christiansen HE, Hegde MR, Bank RA, Pals G, Ankala A, Conneely K, Seaver L, Yandow SM, Raney E, Babovic-Vuksanovic D, Stoler J, Ben-Neriah Z, Segel R, Lieberman S, Siderius L, Al-Aqeel A, Hannibal M, Hudgins L, McPherson E, Clemens

- M, Sussman MD, Steiner RD, Mahan J, Smith R, Anyane-Yeboa K, Wynn J, Chong K, Uster T, Aftimos S, Sutton VR, Davis EC, Kim LS, Weis MA, Eyre D, Byers PH. Mutations in FKBP10, which result in Bruck syndrome and recessive forms of osteogenesis imperfecta, inhibit the hydroxylation of telopeptide lysines on bone collagen. *Hum Mol Genet.* 2012
15. Martinez-Glez V, Valencia M, Caparrós-Martin JA, Aglan M, Temtamy S, Tenorio J, Pulido V, Lindert U, Rohrbach M, Eyre D, Giunta C, Lapunzina P, Ruiz-Perez VL. Identification of a mutation causing deficient BMP1m/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta. *Hum Mutat.* 2012; 33:343–350. [PubMed: 22052668]
 16. Asharani PV, Keupp K, Semler O, Wang W, Li Y, Thiele H, Yigi G, Pohl E, Becker J, Frommolt P, Sonntag C, Altmüller J, Zimmermann K, Greenspan DS, Akarsu NA, Netzer C, Schönau E, Wirth R, Hammerschmidt M, Nürnberg P, Sollnik B, Carney TJ. Attenuated BMP1 function compromises osteogenesis, leading to bone fragility in humans and zebrafish. *Am J Hum Genet.* 2012; 90:661–674. [PubMed: 22482805]
 17. Cundy T. Recent advances in osteogenesis imperfecta. *Calcif Tissue Int.* 2012; 90:439–449. [PubMed: 22451222]
 18. Vranka JA, Sakai LY, Bächinger HP. Prolyl 3-hydroxylase 1, enzyme characterization and identification of a novel family of enzymes. *J Biol Chem.* 2004; 279:23615–23621. [PubMed: 15044469]
 19. Weis MA, Hudson DM, Kim L, Scott M, Wu JJ, Eyre DR. Location of 3-hydroxyproline residues in collagen types I, II, III and V/XI implies a role in fibril supramolecular assembly. *J Biol Chem.* 2010; 285(4):2580–2590. PMC2807315. [PubMed: 19940144]
 20. Becker J, Semler O, Gilissen C, Li Y, Bolz HJ, Giunta C, Bergmann C, Rohrbach M, Koerber F, Zimmermann K. Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. *Am J Hum Genet.* 2011; 88:362–371. [PubMed: 21353196]
 21. Homan EP, Rauch F, Grafe I, Lietman C, Doll JA, Dawson B, Bertin T, Napierala D, Morello R, Gibbs R, White L, Miki R, Cohn DH, Crawford S, Travers R, Glorieux FH, Lee B. Mutations in *SERPINF1* cause osteogenesis imperfecta type VI. *J Bone Miner Res.* 2011; 26:2798–803. [PubMed: 21826736]
 22. Cho TJ, Lee KE, Lee SK, Song S, Kim K, Jeon D, Lee G, Kim HN, Lee H, Eom HH, Lee Z, Kim O-H, Park WY, Park S, Ikegawa S, Yoo W, Choi I, Kim JW. A single recurrent mutation in the 5'-UTR of *IFITM5* causes osteogenesis imperfecta type V. *Am J Hum Genet.* 2012; 91:343–348. [PubMed: 22863190]
 23. Semler O, Garbes L, Keupp K, Swan D, Zimmermann K, Becker J, Iden S, Wirth B, Eyse P, Koerber F, Schoenau E, Bohlander SK, Wollnik B, Netzer C. A mutation in the 5'-UTR of *IFITM5* creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus. *Am J Hum Genet.* 2012; 91:349–357. [PubMed: 22863195]
 24. Ha-Vinh R, Alanay Y, Bank RA, Campos-Xavier AB, Zankl A, Superti-Furga A, Bonafé L. Phenotypic and molecular characterization of Bruck syndrome (osteogenesis imperfecta with contractures of the large joints) caused by a recessive mutation in *PLOD2*. *Am J Med Genet A.* 2004; 131:115–120. [PubMed: 15523624]
 25. Bank RA, Robins SP, Wijmenga C, Breslau-Siderius LJ, Bardoel AF, van der Sluijs HA, Puijls HE, TeKoppele JM. Defective collagen crosslinking in bone, but not in ligament or cartilage, in Bruck syndrome: indications for a bone-specific telopeptide lysyl hydroxylase on chromosome 17. *Proc Natl Acad Sci USA.* 1999; 96:1054–1058.
 26. Lapunzina P, Aglan M, Temtamy S, Caparrós-Martin JA, Valencia M, Letón R, Martinez-Glez V, Elhossini R, Arm K, Vilaboa N, Ruiz-Perez VL. Identification of a frameshift mutation in *Osterix* in a patient with recessive osteogenesis imperfecta. *Am J Hum Genet.* 2010; 87:110–114. [PubMed: 20579626]
 27. Korvala J, Jüppner H, Mäkitie O, Sochett E, Schnabel D, Mora S, Bartels CF, Warman ML, Deraska D, Cole WG, Hartikka H, Ala-Kokko L, Männikö M. Mutations in *LRP5* cause primary osteoporosis without features of OI by reducing Wnt signaling activity. *BMC Med Genet.* 2012; 13:26. [PubMed: 22487062]
 28. Cui Y, Niziolek PJ, MacDonald BT, Zylstra CR, Alenina N, Robinson DR, Zhong Z, Matthes S, Jacobsen CM, Conlon RA, Brommage R, Liu Q, Mseeh F, Powell DR, Yang QM, Zambrowicz B,

- Gerrits H, Gossen JA, He X, Bader M, Williams BO, Warman ML, Robling AG. Lrp5 functions in bone to regulate bone mass. *Nat Med.* 2011; 17(6):684–691. [PubMed: 21602802]
29. Niyibizi C, Eyre DR. Identification of the cartilage alpha 1(XI) chain in type V collagen from bovine bone. *FEBS Lett.* 1989; 242:314–218. [PubMed: 2914614]
 30. Wu JJ, Weis MA, Kim LS, Carter BG, Eyre DR. Differences in chain usage and cross-linking specificities of cartilage type V/XI collagen isoforms with age and tissue. *J Biol Chem.* 2009; 284:5539–5545. [PubMed: 19103590]
 31. Eyre DR, Weis MA, Wu JJ. Advances in collagen cross-link analysis. *Methods.* 2008; 45:65–74. [PubMed: 18442706]
 32. Hanson DA, Eyre DR. Molecular site specificity of pyridinoline and pyrrole cross-links in type I collagen of human bone. *J Biol Chem.* 1996; 271(43):26508–26516. [PubMed: 8900119]
 33. Kuypers R, Tyler M, Kurth LB, Jenkins ID, Horgan DJ. Identification of the loci of the collagen-associated Ehrlich chromogen in type I collagen confirms its role as a trivalent cross-link. *Biochem J.* 1992; 283:129–136. [PubMed: 1567360]
 34. Banse X, Devogelaer JP, Lafosse A, Sims TJ, Grynpas M, Bailey AJ. Cross-link profile of bone collagen correlates with structural organization of trabeculae. *Bone.* 2002; 31:70–76. [PubMed: 12110415]
 35. McNab, H.; Monahan, LC. 3-Hydroxypyrrroles. In: Jones, RA., editor. *Chemistry of heterocyclic compounds: Pyrroles, Part 2: The synthesis, reactivity, and physical properties of substituted pyrroles.* Vol. 48. Hoboken, NJ: John Wiley & Sons; 2008.
 36. Kemp PD, Scott JE. Ehrlich chromogens, probable cross-links in elastin and collagen. *Biochem J.* 1986; 252:387–393. [PubMed: 3415661]
 37. Bank RA, TeKoppele JM, Janus GJ, Wassen MH, Pruijs HE, Van der Sluijs HA, Sakkars RJ. Pyridinium cross-links in bone of patients with osteogenesis imperfecta: evidence of a normal intrafibrillar collagen packing. *J Bone Miner Res.* 2000; 15:1330–1336. [PubMed: 10893681]
 38. Eyre D, Shao P, Weis MA, Steinmann B. The kyphoscoliotic type of Ehlers-Danlos syndrome (type VI): differential effects on the hydroxylation of lysine in collagens I and II revealed by analysis of cross-linked telopeptides from urine. *Mol Genet Metab.* 2002; 76:211–216. [PubMed: 12126935]
 39. Rohrbach M, Giunta C. Recessive osteogenesis imperfecta: Clinical, radiological and molecular findings. *Am J Med Genet.* 2012; 160C:175–189. [PubMed: 22791419]
 40. Berg RA, Prockop DJ. The thermal transition of a non-hydroxylated form of collagen. Evidence for a role for hydroxyproline in stabilizing the triple-helix of collagen. *Biochem Biophys Res Commun.* 1973; 52:115–120. [PubMed: 4712181]
 41. Hudson DM, Kim LS, Weis M, Cohn DH, Eyre DR. Peptidyl 3-hydroxyproline binding properties of type I collagen suggest a function in fibril supramolecular assembly. *Biochemistry.* 2012; 51:2417–2424. [PubMed: 22380708]
 42. Schumacher MA, Mizuno K, Bächinger HP. The crystal structure of a collagen-like polypeptide with 3(S)-hydroxyproline residues in the Xaa position forms a standard 7/2 collagen triple helix. *J Biol Chem.* 2006; 281:27566–27574. [PubMed: 16798737]
 43. Yang C, Park AC, Davis NA, Russell JD, Kim B, Brand DD, Lawrence MJ, Ge Y, Westphall MS, Coon JJ, Greenspan DS. Comprehensive mass spectrometric mapping of the hydroxylated amino acid residues of the $\alpha 1(V)$ collagen chain. *J Biol Chem.* 2012
 44. Sweeney SM, Orgel JP, Fertala A, McAuliffe JD, Turner KR, Di Lullo GA, Chen S, Antipova O, Perumal S, Ala-Kokko L, Forlino A, Cabral WA, Barnes AM, Marini JC, San Antonio JD. Candidate cell and matrix interaction domains on the collagen fibril, the predominant protein of vertebrates. *J Biol Chem.* 2008; 283:21187–21197. [PubMed: 18487200]
 45. Kalamajski S, Oldberg Å. The role of small leucine-rich proteoglycans in collagen fibrillogenesis. *Matrix Biol.* 2010; 29:248–253. [PubMed: 20080181]
 46. Ehrlich H, Deutzmann R, Brunner E, Cappellini E, Koon H, Solazzo C, Yang Y, Ashford D, Thomas-Oates J, Lubeck M, Baessmann C, Langrock T, Hoffmann R, Wörheide G, Reitner J, Simon P, Tsurkan M, Ereskovsky AV, Kurek D, Bazhenov VV, Hunoldt S, Mertig M, Vyalikh DV, Molodtsov SL, Kummer K, Worch H, Smetacek V, Collins MJ. Mineralization of the metre-

- long biosilica structures of glass sponges is template on hydroxylated collagen. *Nature Chem.* 2010; 2:1084–1088. [PubMed: 21107374]
47. Donoghue PCJ, Sansom IJ, Downs JP. Early evolution of vertebrate skeletal tissues and cellular interactions, and the canalization of skeletal development. *J Experiment Zool (Mol Dev Evol)*. 2006; 306B:278–294.
 48. Widmer C, Gebauer JM, Brunstein E, Rosenbaum S, Zaucke F, Drögemüller C, Leeb T, Baumann U. Molecular basis for the action of the collagen-specific chaperone Hsp47/SERPINH1 and its structure-specific client recognition. *PNAS*. 2012; 109(33):13243–13247. [PubMed: 22847422]
 49. Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. *J Bone Miner Res*. 2002; 17:30–38. [PubMed: 11771667]
 50. Lindahl K, Barnes AM, Fratzl-Zelman N, Whyte MP, Hefferan TE, Makareeva E, Brusel M, Yaszemski MJ, Rubin C-J, Kindmark A, Roschger P, Klaushofer K, McAlister WH, Mumm S, Leikin S, Kessler E, Boskey AL, Ljunggren O, Marini JC. *COL1C*-propeptide cleavage site mutations cause high bone mass osteogenesis imperfecta. *Hum Mutat*. 2011; 32:598–609. [PubMed: 21344539]
 51. Uzel MI, Scott IC, Babakhanlou-Chase H, Palamakumbura AH, Pappano WM, Hong H-H, Greenspan DS, Trackman PC. Multiple bone morphogenetic protein 1-related mammalian metalloproteinases process pro-lysyl oxidase at the correct physiological site and control lysyl oxidase activation in mouse embryo fibroblast cultures. *J Biol Chem*. 2001; 276:22537–22543. [PubMed: 11313359]
 52. Moffatt P, Gaumond M-H, Salois P, Sellin K, Bessette M-C, Godin E, Tambasco de Oliveira P, Atkins GJ, Nanci A, Thomas G. Bril: A novel bone-specific modulator of mineralization. *J Bone Miner Res*. 2008; 23:1497–1507. [PubMed: 18442316]
 53. Hanagata N, Li X, Morita H, Takemura T, Li J, Minowa T. Characterization of the osteoblast-specific transmembrane protein IFITM5 and analysis of IFITM5-deficient mice. *J Bone Miner Metab*. 2011; 29:279–290. [PubMed: 20838829]
 54. Nikitovic D, Aggelidakis J, Young MF, Iozzo RV, Karamanos NK, Tzanakakis GN. The biology of small leucine-rich proteoglycans in bone pathophysiology. *J Biol Chem*. 2012:33926–33933. [PubMed: 22879588]
 55. Nikdin H, Olsson M-L, Hultenby K, Sugars RV. Osteoadherin accumulates in the predentin towards the mineralization front in the developing tooth. *PLoS ONE*. 2012; 7:1–12.
 56. Vanleene M, Porter A, Guillot P-V, Boyde A, Oyen M, Shefelbine S. Ultra-structural defects cause low bone matrix stiffness despite high mineralization in osteogenesis imperfecta mice. *Bone*. 2012; 50:1317–1323. [PubMed: 22449447]
 57. Shapiro JR, Lietman C, Grover M, Lu JT, Nagamani SCS, Dawson BC, Baldrige DM, Bainbridge MN, Cohn DH, Blazo M, Robers TT, Brennen F-S, Wu Y, Gibbs RA, Melvin P, Campeau PM, Lee BH. Phenotypic variability of Osteogenesis Imperfecta type V caused by an *IFITM5* mutation. *J Bone Miner Res*. 2013

Fig. 1. Transmission electron micrograph of decalcified bone matrix showing the dense, woven packing arrangement of collagen fibrils. Inset: individual fibrils are a covalently cross-linked composite of collagen type I polymerized on a template of type V collagen.

Fig. 2.

A As well as a characteristic fibril organization, the pathway of covalent intermolecular cross-linking in bone collagen is unique in using precursor aldehydes produced by lysyl oxidase from both lysines and hydroxylysines in telopeptide domains. The resulting mature cross-links consist of both pyridinolines and pyrroles in about equal amounts.

B Three lysyl hydroxylases (LH1, LH2 and LH3) encoded by three different genes (*PLOD1*, *PLOD2* and *PLOD3*) regulate the chemical nature of the cross-links, which varies between different tissue types. In bone collagen LH2 partially hydroxylates telopeptide lysines at both ends of the type I collagen molecule and LH1 partially hydroxylates the two helical site lysines in $\alpha 1(I)$ and $\alpha 2(I)$ chains. In addition, the hydroxylysines at K87 in $\alpha 1(I)$ and $\alpha 2(I)$ are mostly glycosylated with a single galactose residue with lesser amounts of glucosyl galactose. This pattern is a distinguishing unique post-translational feature of bone type I collagen compared with type I collagen of skin, tendon and other soft tissues.

3Hyp Sites

Procollagen molecules

Fig. 3.

Location of 3Hyp residues in type I and V collagen molecules (A) with their resulting aligned positions in a fibril relative to the D-periodic stagger and band pattern of fibrils as seen by transmission EM (B). A single fully 3-hydroxylated proline occurs at Pro986 (A1 site) in $\alpha 1(I)$ and at Pro707 (A3 site) in $\alpha 2(I)$. All four sites (A1 – A4) are fully or partially 3-hydroxylated in $\alpha 2(V)$, and the spacing between A2, A3 and A4 is D-periodic (234 ± 3 residues). Multiple sites of 3Hyp occur in the $\alpha 1(V)$ chain (19,41) with a high occupancy and D-periodic spacing of B1 and B3 (19). It is notable that fibril surface binding sites for one class of small leucine-rich proteoglycans (e.g., fibromodulin, lumican) are close to 3Hyp sites.

Table 1

Non-collagen Genes in which Mutations Cause Osteogenesis Imperfecta Variants

Gene	Protein	Phenotype	Bone Collagen Abnormalities
<i>CRTAP</i> <i>LEPRE1</i> <i>PPIB</i>	}	AR, bone fragility, reduced mineral density	1(I)P986 and 2(I)P707 under prolyl-3-hydroxylation, high HP/LP (CRTAP & LEPRE1), low HP/LP (PPIB)
<i>FKBP10</i> <i>PLOD2</i>	}	AR, Bruck Syndrome: bone fragility, joint contractures	Lack of telopeptide hydroxylysines produces skin-like cross-links
<i>SERPINH1</i>	HSP47, heat shock protein 47	AR, bone fragility (type III OI)	High HP/LP, and abnormal arrangement of cross-linking bonds
<i>SERPINF1</i>	PEDF pigment epithelium-derived factor	AR, bone fragility and low mineral density, osteoid seams	Failed mineralization, no other collagen abnormalities
<i>BMP1</i>	Procollagen type I C-propeptidase	AR, bone fragility, high mineral density	Defective C-propeptide removal, potential cross-linking defects
<i>IFITM5</i>	Bril, osteoblast-specific small transmembrane protein	AD, bone fragility, hyperplastic callus (type V OI)	None reported